Compound
The drug is produced in the form of tablets containing 500 mg of mefenamic acid + methylcellulose, magnesium stearate, potato starch, croscarmellose sodium, octadecanoic acid.
The medicine is also sold in capsules of 250 or 500 mg of mefenamic acid + talc, lactose monohydrate, corn starch, colloidal silicon dioxide, crospovidone, sodium lauryl sulfate, crospovidone.
Another product can be purchased in the form of a powder for preparing medicines.
Pharmacodynamics and pharmacokinetics
The active ingredient of the drug is an anthranilic acid , belongs to the group of NSAIDs and antirheumatic drugs. Thanks to its chem. properties have analgesic, anti-inflammatory, antipyretic effects.
The drug is able to reduce the intensity of the body's production of specific inflammatory mediators - serotonin and prostaglandins . The drug affects both the processes occurring in the periphery and the central mechanisms of increasing pain sensitivity, reduces the activity of lysosome proteases .
Mefenamic acid stabilizes protein ultrastructures and cell membranes, relieves swelling and reduces capillary permeability.
The antipyretic effect of the drug is due to the ability of the acid to influence the thermoregulation center in the brain and reduce the synthesis of inflammatory mediators.
The drug also has a moderate antiviral effect, stimulating the production of interferon , increasing the content of T helper cells and T lymphocytes .
3 hours after oral administration, the active substance reaches its maximum concentration in the blood . There is a linear relationship between the dose taken and the concentration of the drug in the blood plasma . The drug binds very well to proteins and undergoes metabolic in the liver.
The half-life ranges from 120 to 240 minutes. The product is excreted in feces and urine.
Pharmacological properties of the drug Mefenamic acid-Darnitsa
Mefenamic acid is an NSAID. The mechanism of anti-inflammatory action is due to the ability to inhibit the synthesis of inflammatory mediators (prostaglandins, serotonin, kinins, etc.) and reduce the activity of lysosomal enzymes involved in the inflammatory reaction. Mefenamic acid stabilizes protein ultrastructures and cell membranes, reduces vascular permeability, disrupts oxidative phosphorylation processes, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation at the site of inflammation, increases cell resistance and stimulates wound healing. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center. In the mechanism of analgesic action, along with the influence on the central mechanisms of pain sensitivity, a significant role is played by the local effect on the site of inflammation and the ability to inhibit the formation of algogens (kinins, histamine, serotonin). Unlike most other NSAIDs, Mefenamic acid-Darnitsa stimulates the formation of interferon. After oral administration, mefenamic acid is quickly and fairly completely absorbed from the digestive tract. The maximum concentration in the blood serum is observed 2–4 hours after administration, the level in the blood is proportional to the dose taken. The equilibrium concentration (20 mcg/ml) is determined on the 2nd day of use (1 g 4 times a day). Binds 90% to blood albumin. In the liver it forms metabolites by oxidation, hydrolysis, glucuronidation. The half-life (T1/2) is 2–4 hours. It is excreted from the body unchanged and in the form of metabolites mainly through the kidneys (67% of the dose), with feces (20–25%).
Indications for use
The drug has a fairly wide range of applications:
- acute respiratory infections , viruses , influenza ;
- diseases of the musculoskeletal system , rheumatism , rheumatoid arthritis , ankylosing spondylitis ;
- primary dysmenorrhea and dysfunctional menorrhagia ;
- pain, swelling , inflammation after operations and injuries.
Mefenamic acid also prescribed for fever and fever .
Indications for use of the drug Mefenamic acid-Darnitsa
For the purpose of prevention and treatment of influenza and acute respiratory viral infections; inflammatory diseases of the musculoskeletal system: rheumatoid, gouty arthritis, rheumatism, ankylosing spondylitis (ankylosing spondylitis). Pain syndrome: ossalgia, neuralgia, myalgia, arthralgia, radiculitis, headache, pain during menstrual syndrome, childbirth (as an analgesic and tocolytic agent); in orthopedic surgery; for oncological diseases; for algodismenorrhea (can be used as a drug of choice for the treatment of moderate pain if it is necessary to use NSAIDs for more than 1 week). For local use: periodontitis (dystrophic-inflammatory forms), erosive and ulcerative lesions of the oral mucosa. Menorrhagia (associated with adenomyomas, the presence of intrauterine contraceptives, etc.).
Contraindications
The product is contraindicated:
- if you are allergic to its components;
- if after taking Aspirin or other NSAIDs the patient develops Quincke's edema , runny nose , bronchospasm , urticaria or bronchial asthma ;
- combine with specific COX-2 inhibitors ;
- with a stomach or duodenal ulcer , including a history of it;
- pregnant and lactating women;
- for inflammatory bowel diseases, diseases of the hematopoietic organs;
- children under 5 years old;
- if the patient suffers from severe heart failure, liver or kidney disease;
- with perforation or gastrointestinal bleeding.
The medicine is prescribed with caution to patients with epilepsy , arterial hypertension , coronary heart disease , systemic lupus erythematosus , ulcerative colitis and Crohn's disease (with a history).
Elderly people are at risk; their likelihood of developing side effects increases significantly.
Special instructions for the use of the drug Mefenamic acid-Darnitsa
The drug is prescribed with caution to patients with a history of allergic reactions to acetylsalicylic acid and other NSAIDs; Prescribe with caution to patients with a history of peptic ulcer of the stomach or duodenum. Use during pregnancy or breastfeeding. The drug is contraindicated during pregnancy. If it is necessary to use the drug during breastfeeding, breastfeeding should be discontinued. Ability to drive vehicles and operate other machinery . The drug can affect the speed of reactions when driving vehicles and when working with mechanisms that require increased attention. Children. The drug is contraindicated in children under 5 years of age.
Side effects
Mefenamic acid may cause:
- drowsiness , weakness, irritability, headaches , convulsions , blurred vision;
- pain in the abdomen or stomach, nausea, increased gas formation , vomiting;
- increased levels enzymes ;
- colitis , heartburn , enterocolitis , hepatitis , jaundice , pancreatitis ;
- increased blood pressure , arrhythmia ;
- gastritis , peptic ulcers without bleeding or with bleeding, constipation , diarrhea ;
- dyspnea , bronchospasm ;
- skin rashes, peripheral edema, angioedema , Stevens-Johnson syndrome , urticaria , photosensitivity , asthma , anaphylaxis ;
- rarely - congestive heart failure, peripheral , palpitations, shortness of breath ;
- capillary necrosis , polyuria ;
- aseptic meningitis glucose tolerance in patients with diabetes mellitus ;
- cystitis , dysuria , hematuria , renal failure , nephrotic syndrome ;
- aplastic anemia , decreased blood clotting, leukopenia , thrombocytopenia , agranulocytosis , pancytopenia , neutropenia ;
- hyponatremia , hyperkalemia , glomerulonephritis ;
- ringing in the ears, loss of color vision (reversible), eye irritation.
Side effects of the drug Mefenamic acid-Darnitsa
From the gastrointestinal tract: pain in the epigastric region, anorexia, heartburn, nausea, flatulence, dyspepsia, constipation, diarrhea. Increased levels of liver enzymes in blood plasma. From the respiratory system : dyspnea, bronchospasm. From the urinary system: dysuria, cystitis, renal dysfunction, albuminuria, hematuria, oliguria or polyuria. From the blood system: anemia, prolongation of bleeding time, eosinophilia, leukopenia, thrombocytopenia. From the central nervous system: drowsiness or insomnia, weakness, irritability. Skin: allergic reactions; skin rashes, itching, swelling of the face.
Instructions for Mefenamic acid (method and dosage)
The medicine is prescribed orally, after meals.
It is not advisable to split the capsules; it is better to swallow them whole.
Adults are usually prescribed 250 or 500 mg of the drug 3-4 times a day. The maximum daily dosage is 3 grams. As a rule, after achieving the desired effect, the daily dosage is reduced to one gram.
The course of treatment is determined by the attending physician. For example, for fever or for the treatment of pain, the duration of therapy is up to 7 days. The course of treatment for joint diseases ranges from 20 to 60 days.
Instructions for Mefenamic acid for children
The drug should not be prescribed to children under 5 years of age.
The dosage for children aged 5 to 12 years should not exceed one gram. As a rule, take 250 mg 3 or 4 times a day.
The course of treatment is determined by the doctor.
Mefenamine instructions for use
Instructions for medical use of the drug Mefenaminka
Composition 1 tablet contains mefenamic acid 500 mg excipients: lactose, sodium lauryl sulfate, povidone, crospovidone, corn starch, colloidal silicon dioxide, microcrystalline cellulose, talc, magnesium stearate, opadry 200 white.
Dosage form. Film-coated tablets. Basic physical and chemical properties: elongated tablets with a chamfer, with a notch, coated with a white or almost white film.
Pharmacological group. Non-steroidal anti-inflammatory drugs. ATX code M01A G01.
Pharmacological properties. Pharmacodynamics. Mefenamic acid is an NSAID. The mechanism of anti-inflammatory action is due to the ability to inhibit the synthesis of inflammatory mediators (prostaglandins, serotonin, kinins, etc.) and reduce the activity of lysosomal enzymes involved in the inflammatory reaction. Mefenamic acid stabilizes protein ultrastructures and cell membranes, reduces vascular permeability, disrupts oxidative phosphorylation processes, suppresses the synthesis of mucopolysaccharides, inhibits cell proliferation at the site of inflammation, increases cell resistance and stimulates wound healing. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center. Mefenamic acid stimulates the formation of interferon. In the mechanism of analgesic action, along with the influence on the central mechanisms of pain sensitivity, a significant role is played by the local effect on the site of inflammation and the ability to inhibit the formation of algogens (kinins, histamine, serotonin).
Pharmacokinetics. After oral administration, mefenamic acid is quickly and fairly completely absorbed from the digestive tract. The maximum concentration in the blood is reached 2-4 hours after administration. The blood level is proportional to the dose. The equilibrium concentration (20 mcg/ml) is determined on the 2nd day of use (1 g 4 times a day). Binds 90% to blood albumin. In the liver it forms metabolites by oxidation, hydrolysis, glucuronidation. The half-life (T1/2) is 2-4 hours. It is excreted from the body unchanged and in the form of metabolites mainly by the kidneys (67% of the dose) and with feces (20-25%).
Indications. Acute respiratory viral infections and influenza. Pain of low and medium intensity: muscle, joint, traumatic, dental, headache of various etiologies, postoperative and postpartum pain. Primary dysmenorrhea. Dysfunctional menorrhagia, including those caused by the presence of intrauterine contraceptives, in the absence of pathology of the pelvic organs. Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis. Contraindications. Hypersensitivity to the components of the drug. Bronchospasm, Quincke's edema, rhinitis, bronchial asthma, urticaria in history, which occurred after the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Simultaneous administration of specific COX-2 inhibitors. Peptic ulcer of the stomach and duodenum, including a history of inflammatory bowel disease, diseases of the hematopoietic organs, severe heart failure, severe liver or kidney dysfunction, gastrointestinal bleeding or perforation caused by taking non-steroidal anti-inflammatory drugs.
Interaction with other drugs and other types of interactions. Thiamine, pyridoxine hydrochloride, barbiturates, phenothiazine derivatives, narcotic analgesics, caffeine, diphenhydramine increase the analgesic effect of the drug. When used together, mefenamic acid and methotrexate increase the toxic effects of methotrexate. Antihypertensive drugs (ACE inhibitors and angiotensin II receptor antagonists): decreased antihypertensive effect. Diuretics: decreased diuretic effect. Diuretics may increase the nephrotoxicity of NSAIDs. Cardiac glycosides: NSAIDs may worsen heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. Cyclosporines: increased risk of nephrotoxicity. Mefipristone NSAIDs should not be taken within 8-12 days of taking mefipristone; NSAIDs may reduce the effects of mefipristone. Corticosteroids: increased risk of gastrointestinal ulcers and bleeding. Antiplatelet agents and selective serotonin reuptake inhibitors: increased risk of gastrointestinal bleeding. Fluoroquinolones NSAIDs increase the risk of seizures. Aminoglycosides NSAIDs increase the risk of nephrotoxicity. Tacrolimus increases the risk of nephrotoxicity. Zidovudine NSAIDs increase the risk of hematological toxicity. The risk of joint hemorrhage and hematoma increases in HIV-positive hemophiliacs who are simultaneously treated with zidovudine. Lithium preparations reduce the excretion of lithium and increase the risk of developing lithium toxicity. Mefenamic acid increases the activity of oral anticoagulants, so their simultaneous use increases the risk of bleeding. Concomitant use with other non-steroidal anti-inflammatory drugs increases the anti-inflammatory effect and the likelihood of side effects from the gastrointestinal tract.
Features of application. Prescribe with caution to patients with acute cardiovascular failure, arterial hypertension, and coronary heart disease. Prescribe with caution to patients with epilepsy. There are no special recommendations for the use of the drug for moderate impairment of liver or kidney function. NSAIDs should be taken with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), since exacerbation of the disease is possible. Elderly patients usually have an increased risk of developing side effects from the gastrointestinal tract, so treatment should be started with a minimum dose. Patients with systemic lupus erythematosus and mixed connective tissue diseases are at increased risk of aseptic meningitis. Mefenamic acid should be discontinued at the first appearance of skin rash, mucosal damage, or any other manifestation of hypersensitivity. Taking mefenamic acid may impair female fertility and is not recommended for women who are trying to become pregnant.
Use during pregnancy or breastfeeding. The drug is used by women during pregnancy and breastfeeding.
The ability to influence the reaction rate when driving vehicles or other mechanisms. Caution should be exercised when driving vehicles or working with mechanisms that require increased attention, since sometimes the use of the drug can cause drowsiness, blurred vision, and convulsions.
Method of administration and dose. The drug should be used under the supervision of a physician, who determines the dose and duration of treatment. Use internally. The drug should be taken after meals with milk. Adults and children over 12 years old: 250-500 mg 3-4 times a day. According to indications and if well tolerated, the dose is increased to a maximum of 3000 mg; after achieving a therapeutic effect, the dose is reduced to 1000 mg / day. Children aged 5 to 12 years - 250 mg 3-4 times a day. The course of treatment for joint diseases can last from 20 days to 2 months or more. When treating pain syndrome, the course of treatment lasts up to 7 days.
Children. The drug is contraindicated in children under 5 years of age. Overdose. Symptoms: pain in the epigastric region, nausea, vomiting, drowsiness. In severe cases - gastrointestinal bleeding, respiratory depression, arterial hypertension, twitching of individual muscle groups, coma. Treatment. There is no specific antidote. Gastric lavage with a suspension of activated carbon. Alkalinization of urine, forced diuresis. Symptomatic therapy. Hemosorption and hemodialysis are ineffective due to the strong binding of mefenamic acid to blood proteins. Adverse reactions. From the digestive tract: pain in the epigastric region, anorexia, heartburn, nausea, flatulence, vomiting, enterocolitis, colitis, steatorrhea, cholestatic jaundice, hepatitis, pancreatitis, hepatorenal syndrome, hemorrhagic gastritis, ulcer, with or without bleeding. Gastrointestinal bleeding, dyspepsia, constipation, diarrhea. Increased levels of liver enzymes in blood plasma. From the cardiovascular system: arterial hypertension, arrhythmia, rarely - congestive heart failure, peripheral edema, fainting, arterial hypotension, palpitations, shortness of breath. From the respiratory system: shortness of breath, bronchospasm. From the urinary system: dysuria, cystitis. Impaired renal function, albuminuria, hematuria, oliguria or polyuria, renal failure, including papillary necrosis, acute interstitial nephritis, nephrotic syndrome, allergic glomerulonephritis, hyponatremia, hyperkalemia. Blood disorders: aplastic anemia, autoimmune hemolytic anemia, increased bleeding time, eosinophilia, leukopenia, thrombocytopenia, decreased hematocrit, thrombocytopenic purpura, agranulocytosis, neutropenia, pancytopenia, bone marrow hypoplasia. From the nervous system: drowsiness or insomnia, weakness, irritability, agitation, headache, blurred vision, convulsions. From the senses: ringing in the ears, otalgia, visual disturbances, reverse loss of the ability to distinguish colors, eye irritation. Allergic reactions: skin rashes, skin itching, facial swelling, allergic rhinitis, angioedema, laryngeal edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, urticaria, bullous pemphigus, photosensitivity, asthma, anaphylactic shock. Other: impaired glucose tolerance in patients with diabetes mellitus, aseptic meningitis.
Best before date. 2 years.
Storage conditions. Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children. Package. 10 tablets in a blister pack; 2 contour packs per pack.
Vacation category. Over the counter.
Manufacturer. JSC "Pharmaceutical"
The location of the manufacturer and its address of place of business. Ukraine, 02093, Kiev, st. Boryspilskaya, 13.
Overdose
In case of overdose, the following are observed: abdominal pain, drowsiness , nausea, vomiting, gastrointestinal bleeding , respiratory depression, convulsions, decreased blood pressure , coma .
The medicine does not have a specific antidote . Treatment options include gastric lavage, enterosorbents , forced diuresis , and urine acidification. Hemodialysis is ineffective.
Interaction
Antihypertensive drugs and ACE inhibitors , when combined with this drug, lose their ability to lower blood pressure .
When combining the drug with Thiamine , Pyridoxine Phenothiazine derivatives , caffeine , narcotic analgesics , Diphenhydramine or barbiturates analgesic effect increases .
Fluoroquinolones increase the risk of seizures, aminoglycosides and tacrolimus - nephrotoxicity.
The medicine increases the toxicity of Methotrexate .
The combined use of the drug with cardiac glycosides can increase the degree of heart failure and increase the level of glycosides in the blood.
Diuretics and Cyclosporine increase the nephrotoxicity of mefenamic acid , and the diuretic effect of diuretics .
The interval between taking Mifepristone and Meph. acid should be at least 8-12 days.
When combining the drug with corticosteroids , selective serotonin reuptake inhibitors or antiplatelet agents, the risk of gastrointestinal bleeding and perforation .
Caution should be used when combining the medicine with lithium , zidovudine , oral anticoagulants , and other NSAIDs .
Drug interactions Mefenamic acid-Darnitsa
Opioid analgesics, antithrombotics, vitamin K antagonists, pyridoxine, thiamine, phenothiazine derivatives enhance the effect of mefenamic acid. When mefenamic acid and methotrexate are used together, the toxic effects of the latter are enhanced. When used together with warfarin, the risk of gastrointestinal bleeding increases. When mefenamic acid is used concomitantly with antacids, the maximum plasma concentration of mefenamic acid increases and the AUC increases.
special instructions
In case of skin rashes, damage to the mucous membrane or other manifestations hypersensitivity reactions , discontinue use and consult a doctor.
Taking the drug can cause fertility in women, so it should not be prescribed to women who are trying to conceive a child.
While taking the medicine, it is best to refrain from driving or operating machinery.
In order to reduce the likelihood of developing side effects from the gastrointestinal tract, it is recommended to take tablets or capsules with milk.
Reviews about Mefenamic acid
There are good reviews about the medicine on the Internet. It quickly and permanently brings down the temperature, does not cause adverse reactions, and has antiviral activity. Many are satisfied with the low cost of the drug.
Reviews about the medicine:
“My child is often sick. Mefenamic acid is the only thing that helps us. I give it probably from the age of 4, now the child is 8 years old”;
“I always have a place in my medicine cabinet for the anti-inflammatory drug Mefenamic acid. This medicine often helps out when there is a high fever that needs to be brought down quickly, and it helps with the first symptoms of a cold or flu. It is easily tolerated and does not cause discomfort during use”;
“My oldest boy is 10 years old, we have been saving him since he was 5. The tablets reduce the temperature within 1 hour. I am glad that such a drug exists; not a single suppository or tablet helped us, only Mefenamic acid saved us. Now I always keep it in stock at home.”
Mefenamic acid price
The price of tablets with mefenamic acid is approximately 50 UAH for 20 pieces, with a dosage of 500 mg. The cost of capsules is 60 UAH for the same amount of medicine.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
LuxPharma* special offer
- Mefenamic acid (Mefenaminka) tab.
500 mg N20 RUB 1,380 order
show more
Pharmacy24
- Mefenamic acid-Darnitsa 500 mg N20 tablets PrAT" Pharmaceutical company "Darnitsa", Ukraine
46 UAH. order - Mefenamic acid 250 mg N20 capsules Flamingo Pharmaceuticals Ltd, India
40 UAH order
